Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127393831 | 12739383 | 1 | I | 20160718 | 20160718 | 20160913 | 20160913 | EXP | CA-PFIZER INC-2016354138 | PFIZER | 60.00 | YR | M | Y | 0.00000 | 20160913 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127393831 | 12739383 | 1 | PS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 5 MG, 2X/DAY | 203214 | 5 | MG | TABLET | BID | ||||||
| 127393831 | 12739383 | 2 | SS | SULFASALAZINE. | SULFASALAZINE | 1 | Oral | UNK | 7073 | ||||||||||
| 127393831 | 12739383 | 3 | C | OXYCONTIN | OXYCODONE HYDROCHLORIDE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127393831 | 12739383 | 1 | Rheumatoid arthritis |
| 127393831 | 12739383 | 2 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127393831 | 12739383 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127393831 | 12739383 | Arthralgia | |
| 127393831 | 12739383 | Death |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127393831 | 12739383 | 1 | 20141107 | 0 |